UnitedHealthcare Bariatric Surgery Coverage Update | OpenPayer
DraftUnitedHealthcarePolicy CS007KY.11
Bariatric Surgery (for Kentucky Only)
Defines UnitedHealthcare Kentucky clinical coverage stance, criteria sources, definitions, and coding references for bariatric and metabolic surgical procedures for adults and adolescents; applies only to Kentucky members and providers.
Policy Summary
PayerUnitedHealthcare
PolicyBariatric Surgery (for Kentucky Only)
Policy CodePolicy CS007KY.11
Change TypeCoverage language revisedcode added
Effective DateMay 1, 2025
Next Review Date
Key ActionRequest prior authorization per InterQual Bariatric/Metabolic Surgery criteria and document multidisciplinary evaluation.
Removed language indicating a list of specific bariatric surgical procedures are proven and medically necessary.
Added CPT code 43999 to Applicable Codes.
Updated Description of Services, Clinical Evidence, and References sections to reflect the most current information.
Updated related policies link/title for Minimally Invasive Procedures for the Treatment of Upper Gastrointestinal Diseases (for Kentucky Only).
2025-05-01Effective date
KentuckyGeographic applicability
InterQualClinical criteria source
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.
43999
CPT code added
≥12Unproven procedures listed
Coverage Criteria and Rationale
InterQual-based coverage
Medical necessity and coverage follow the referenced InterQual clinical pathways; providers must use InterQual for specific inclusion/exclusion criteria and documentation requirements.
InterQual-based medical necessity: Medical necessity and clinical coverage criteria for bariatric and metabolic surgery (including adolescents) are determined by the referenced InterQual CP: Bariatric or Metabolic Surgery and Bariatric or Metabolic Surgery (Adolescent).see InterQual
Providers must refer to InterQual for specific numeric thresholds, inclusion/exclusion criteria, and documentation requirements.
Unproven / Not Medically Necessary Procedures
The following procedures are listed in the policy as unproven or not medically necessary for routine treatment of obesity due to insufficient evidence of efficacy or safety:
Unproven / Not Medically Necessary Procedures: Bariatric surgery as the primary treatment for any condition other than obesity; bariatric artery embolization (BAE); gastric electrical stimulation with an implantable gastric stimulator (IGS); gastrointestinal liners (e.g., EndoBarrier); intragastric balloon (IGB); laparoscopic greater curvature plication (total gastric vertical plication); mini-gastric bypass (MGB)/laparoscopic mini-gastric bypass (LMGBP)/one-anastomosis gastric bypass (OAGB); single-anastomosis duodenal switch/SIPS; stomach aspiration therapy (AspireAssist®); transoral endoscopic surgery (including TransPyloric Shuttle® [TPS] device and endoscopic sleeve gastroplasty); and vagus nerve blocking (VBLOC®).N/A
These interventions are explicitly listed as unproven or not medically necessary in the policy.
Covered when described / Evidence summaries
Procedures and devices described in the evidence summary have device-specific regulatory statuses, typical usage durations, or required adjunctive care that affect coverage evaluation:
Device regulatory/usage statements: TransPyloric Shuttle (TPS): FDA premarket approval for up to 12 months of therapy for patients with BMI 35.0–40.0 kg/m² or BMI 30.0–34.9 kg/m² with ≥1 obesity-related comorbid condition; Intragastric balloons (IGBs): typically used as a temporary adjunct to diet/exercise with recommended maximum placement duration ~6 months; Gastrointestinal liners (EndoBarrier): not FDA-approved in the U.S. and limited to investigational use only.device-specific
See device labeling and FDA approvals for exact indications and maximum placement durations.
Revisional surgery considerations: Revisional bariatric surgery indications vary by index procedure and complication; prior to revisional surgery, a thorough multidisciplinary assessment is required to evaluate anatomic versus behavioral causes of inadequate weight loss or weight regain and to consider individualized risks and benefits.N/A
Multidisciplinary assessment and documentation required before revisional procedures.
Coverage-relevant evidence statements
Evidence-based conclusions in the policy that inform coverage decisions include distinctions between established surgical procedures and newer devices/techniques with limited long-term data:
Established bariatric surgery evidence: Randomized trials and systematic reviews demonstrate that established bariatric procedures (e.g., Roux-en-Y gastric bypass, sleeve gastrectomy) produce greater weight loss and comorbidity improvement compared with non-surgical interventions; evidence quality is moderate and long-term follow-up remains limited in many trials.moderate quality evidence
Cochrane review and comparative trials summarize this evidence.
Procedures with limited long-term evidence or safety concerns: Procedures such as BPD/DS show long-term weight loss but risk nutritional deficiencies; intragastric balloons and other endoscopic devices demonstrate short-term weight loss but unclear long-term durability and higher adverse event/early removal rates; investigational procedures (BAE, GES, LGCP) lack robust RCTs and long-term safety data.evidence gaps or safety signals
See cited trial and systematic review evidence for device-specific limitations.
Evidence-based coverage considerations
Coverage considerations drawn from current evidence emphasize procedure-specific findings that influence coverage judgment and required documentation:
Dual intragastric balloon (DBS) considerations: Randomized evidence (REDUCE trial) shows greater short-term weight loss versus diet/exercise with definable adverse event rates (e.g., balloon deflation, early retrieval, gastric ulcers); longer-term RCT data are lacking and influence coverage limitations.24 weeks primary endpoints
LGCP considerations: Laparoscopic greater curvature plication has mixed and largely nonrandomized evidence with substantial rates of weight regain and revisional surgery in some series, suggesting inferior durability compared with sleeve gastrectomy in available comparative data.variable (1–5 years)
High revision rates reported in retrospective cohorts.
OAGB/MGB and SADIS/SADI considerations:
General requirement for coverage (insufficient evidence)
Overall coverage stance for the technologies reviewed in this section reflects the requirement for robust evidence of safety and sustained effectiveness:
General requirement for coverage: Technologies and procedures reviewed are covered only when safety and effectiveness are established by robust randomized controlled trials and adequate long-term follow-up; currently, many devices and novel procedures lack sufficient high-quality RCTs and long-term outcome data to be routinely covered.evidence standard
Multiple device and procedure sections explicitly cite insufficient evidence and call for larger RCTs and long-term data.
Coverage-relevant clinical criteria and considerations
Professional society guidance and consensus inform patient selection, required adjunctive care, and expectations for multidisciplinary management:
Society-based BMI and candidate criteria: Consider metabolic/bariatric procedures for patients meeting society-recommended BMI thresholds (for example, BMI ≥ 35 kg/m² or ≥ 40 kg/m², and in selected patients with BMI 30.0–34.9 kg/m² with metabolic disease), with consideration of lower BMI thresholds for certain ancestries.see society guidelines
Guidance from ADA, AACE/ASMBS/IFSO, and ASMBS inform threshold adjustments and candidate selection.
IGB candidate and peri-procedure guidance: Intragastric balloon therapy is suggested for patients who have failed conventional weight-loss strategies and should be combined with moderate- to high-intensity lifestyle modification, PPI prophylaxis, perioperative antiemetics, and planned removal within the approved temporary duration.temporary therapy up to 6 months
AGA, ASGE, ASMBS recommendations apply to candidate selection and follow-up.
Guideline-based coverage considerations
Coverage may be considered when multidisciplinary evaluation and guideline-based clinical criteria are satisfied, particularly for adolescents and device-specific indications:
Adolescent MBS eligibility: Adolescent patients meet guideline BMI thresholds (for example, BMI ≥ 120% of the 95th percentile with comorbidity or BMI ≥ 140% of the 95th percentile, or Class II/III definitions per society guidance) AND have documented multidisciplinary evaluation, center expertise, and individualized assessment of physiologic maturity and psychosocial readiness.see pediatric/adolescent guidelines
ASMBS, AAP, and Endocrine Society criteria apply; documentation of multidisciplinary evaluation required.
Temporary device use and governance: Devices with defined temporary indications (e.g., ORBERA IGB up to 6 months; TPS up to 12 months per FDA) may be considered when patient selection, informed consent, and plans for follow-up and adjunctive lifestyle interventions are documented.device-specific (e.g., max 6 months for IGB, 12 months for TPS)
Device labeling and guideline recommendations must be followed and documented.
Guideline and device-indication based coverage considerations
Guideline statements and device labeling that directly affect coverage include BMI thresholds, expedited indications, and device-specific labeling limits:
NICE adult surgical indications: Per NICE, bariatric surgery is an option for people with BMI ≥ 40 kg/m² OR BMI 35–39.9 kg/m² with a significant health condition that could improve with weight loss; expedited consideration is suggested for BMI ≥ 35 or BMI 30–34.9 with recent-onset (≤10 years) type 2 diabetes; lower BMI thresholds may be considered for certain ethnic groups; multidisciplinary care and agreement to long-term follow-up are required.see NICE guidance
NICE guidance (2014, updated 2023) summarizes these indications and requirements.
VA/DoD and society recommendations: VA/DoD and professional societies recommend offering metabolic/bariatric surgery in conjunction with comprehensive lifestyle intervention for adults meeting BMI thresholds and suggest intragastric balloons as an option for short-term (up to 6 months) weight loss in selected patients.see respective guidance
VA/DoD and ASMBS/AACE statements referenced in policy.
Coverage Rationale (revision notice)
Recent policy revisions that affect coverage rationale and coding are summarized below; detailed medical necessity criteria remain referenced to InterQual and other sections of the policy.
Policy revision highlights: Removed prior language that explicitly listed a set of bariatric procedures as proven and medically necessary; added CPT code 43999 to the Applicable Codes list.
See Policy History/Revision Information for specifics; full medical necessity criteria are in InterQual and other policy sections.
Bariatric surgery performed primarily to treat a condition other than obesity is explicitly excluded from coverage and is classified as unproven / not medically necessary. The policy lists bariatric surgery as a primary treatment for non‑obesity indications among procedures that are not supported by sufficient evidence and therefore are not covered under this policy.
The duodenal‑jejunal bypass liner (EndoBarrier™) and similar gastrointestinal liner systems are not FDA‑approved for use in the United States and are limited by federal law to investigational use only. Use of these liners outside approved clinical research contexts is considered investigational and not established as medically necessary.
Bariatric artery embolization (left gastric artery embolization) is considered investigative. Available randomized and observational studies are small, heterogeneous, and limited by short follow‑up, single‑center designs, and variable techniques. The existing evidence base does not establish sustained clinical benefit or long‑term safety, and larger well‑designed RCTs with extended follow‑up are needed before routine coverage can be supported.
Implantable gastric electrical stimulation systems (gastric electrical stimulation, GES) are described as investigational pending larger, well‑designed randomized controlled trials with long‑term follow‑up and consistent safety and efficacy reporting. Small feasibility and cohort studies report some weight‑loss signals, but limitations including small sample sizes, lack of adequate control groups, and limited long‑term outcomes preclude routine coverage at this time.
Intragastric balloon systems, including endoscopically placed and swallowable/ingestible balloons, have mixed evidence: randomized and observational studies show short‑term clinically significant weight loss but high rates of adverse events and frequent weight regain after device removal. Long‑term durability and safety remain uncertain; several assessments conclude evidence is inconclusive and additional robust RCTs with longer follow‑up are required before broad coverage beyond limited or investigational contexts can be recommended. The typical approved placement duration for some IGB devices is 6 months.
Laparoscopic greater curvature plication (LGCP) currently lacks robust comparative long‑term data. Meta‑analyses and single‑center series report inferior weight‑loss outcomes and a higher rate of adverse events and revisional surgery compared with laparoscopic sleeve gastrectomy (LSG). Observational reports of substantial weight regain and a notable proportion of patients requiring revision surgery underscore inadequate evidence of durable benefit and raise concerns about routine coverage of LGCP as a primary bariatric operation.
Comparative data indicate that LGCP may be less effective than sleeve gastrectomy and is associated with higher rates of adverse events and revisions. Given these comparative concerns and the limited long‑term evidence, payers may consider LGCP not preferred as a primary bariatric procedure and may exclude it from routine coverage absent stronger comparative effectiveness and safety data.
This section reviews multiple endoscopic and device‑based therapies for obesity, including stomach aspiration therapy (AspireAssist), transoral endoscopic devices such as the TransPyloric Shuttle (TPS), and endoscopic sleeve gastroplasty (ESG) using systems like OverStitch (Apollo). Across these technologies, evidence is limited by small trials, single‑arm studies, or short follow‑up; many remain investigational or are recommended for use only within research or special‑arrangement frameworks pending higher quality RCTs and long‑term safety data.
Duodenal‑jejunal bypass liners (DJBL/EndoBarrier) have demonstrated short‑term weight loss and some metabolic benefits but are associated with substantial safety concerns, including frequent adverse events (e.g., device obstruction, gastrointestinal hemorrhage, liver abscess, pancreatitis) and high rates of weight regain after removal. Systematic reviews and RCTs are limited and often at high risk of bias; because of the safety profile and lack of durable benefit, DJBL devices are considered experimental or investigational in routine practice.
NICE interventional guidance advises that certain procedures with limited or inadequate evidence—such as the duodenal‑jejunal bypass liner/EndoBarrier, swallowable gastric balloons, and SADI‑S—should only be used in research contexts or with special clinical governance and audit arrangements. These recommendations reflect concerns about limited evidence of efficacy and safety and inform cautious use or restricted commissioning of these interventions.
Surgical intervention in children and young people is generally not recommended except in exceptional circumstances and when physiologic maturity has been achieved. Guidelines emphasize multidisciplinary assessment, documented growth and Tanner staging considerations, and treatment within specialized centers; bariatric procedures for pediatric patients should be reserved for carefully selected cases with comprehensive evaluation and follow‑up.
The current policy revision removed a previously published affirmative list that had explicitly named certain bariatric procedures (for example, adjustable gastric band procedures, biliopancreatic diversion with duodenal switch, Roux‑en‑Y gastric bypass, sleeve gastrectomy, revisional procedures, and related band removals) as proven and medically necessary. That language was deleted in the 05/01/2025 update, reflecting an updated presentation of the evidence and coverage rationale.
The policy enumerates examples of interventions considered unproven or not medically necessary for treating obesity. These include intragastric balloon systems, bariatric artery embolization, implantable gastric electrical stimulation, gastrointestinal liners (e.g., EndoBarrier), mini‑gastric/one‑anastomosis gastric bypass (MGB/OAGB), endoscopic sleeve gastroplasty, vagus nerve blocking (VBLOC), AspireAssist, TPS and other transoral devices, and several other novel or limited‑evidence procedures.
Many endoscopic therapies and device approaches are described as investigational or lacking sufficient long‑term outcome data. The policy highlights that several gastrointestinal liners, transoral devices, ESG, stomach aspiration systems, and similar interventions require additional high‑quality randomized trials and longer follow‑up to establish sustained safety and efficacy before routine coverage can be considered.
A common limitation across the investigational procedures is the absence of adequately powered randomized controlled trials with long‑term follow‑up, heterogeneous study designs, and safety signals such as rehospitalization, device‑related serious adverse events, and nutritional deficiencies. These evidence gaps and safety concerns are cited as reasons these procedures are not established as medically necessary for routine use.
Specific procedures and devices noted as lacking sufficient long‑term randomized controlled trial evidence include certain applications of one‑anastomosis gastric bypass/mini‑gastric bypass (OAGB/MGB), single‑anastomosis duodenal‑ileal switch variants (SADIS/SADI/SADS), and stomach aspiration therapy outside controlled trial contexts. Without robust long‑term RCT data demonstrating durable safety and effectiveness, these procedures are not established as medically necessary for routine coverage.
Because these procedures lack high‑quality evidence of long‑term safety and efficacy, they are not established as medically necessary for routine management of obesity. The policy designates them as investigational or not medically necessary pending further rigorous clinical trials and long‑term outcome data.
Available studies of DJBL/EndoBarrier report high adverse event rates, device‑related serious complications, and frequent weight regain after removal. Given these findings and the limited long‑term RCT evidence, DJBLs raise substantial safety and durability concerns that support their classification as investigational or not medically necessary in routine care.
Fundoplication is not recommended as the procedure of choice for gastroesophageal reflux disease (GERD) in morbidly obese patients (BMI > 35 kg/m²); gastric bypass is preferred because fundoplication does not address obesity or its related comorbidities and has higher failure rates in this population.
NICE interventional procedure guidance recommends limiting procedures with inadequate evidence of efficacy—such as swallowable gastric balloons and other specified interventions—to research settings or special arrangements. This guidance supports restricted use of such technologies until stronger evidence becomes available.
As part of the 05/01/2025 policy revision, the document removed a prior affirmative list that had identified certain procedures as proven and medically necessary; the removal means the policy no longer contains that explicit list and instead focuses on evidence‑based assessments and investigational classifications.
Applicable Codes and Coding Guidance
Intragastric balloon endoscopy codesCPT
0813T
Esophagogastroduodenoscopy, flexible, transoral, with volume adjustment of intragastric bariatric balloon.
43290
Esophagogastroduodenoscopy, flexible, transoral; with deployment of intragastric bariatric balloon
Common laparoscopic bariatric CPT codesCPT
43291
Esophagogastroduodenoscopy, flexible, transoral; with removal of intragastric bariatric balloon(s).
43644
Laparoscopy, surgical, gastric restrictive procedure; with gastric bypass and Roux-en-Y gastroenterostomy (roux limb 150 cm or less).
43645
Laparoscopy, surgical, gastric restrictive procedure; with gastric bypass and small intestine reconstruction to limit absorption.
43647
Laparoscopy, surgical; implantation or replacement of gastric neurostimulator electrodes, antrum.
43648
Laparoscopy, surgical; revision or removal of gastric neurostimulator electrodes, antrum.
43659
Unlisted laparoscopy procedure, stomach.
43770
Laparoscopy, surgical, gastric restrictive procedure; placement of adjustable gastric restrictive device (e.g., gastric band and subcutaneous port components).
Laparoscopy, surgical, gastric restrictive procedure; removal and replacement of adjustable gastric restrictive device component only.
1–10 of 12
1/2
Open bariatric and related procedure CPT codesCPT
43843
Gastric restrictive procedure, without gastric bypass, for morbid obesity; other than vertical-banded gastroplasty.
43845
Gastric restrictive procedure with partial gastrectomy, pylorus-preserving duodenoileostomy and ileoileostomy (50 to 100 cm common channel) to limit absorption (biliopancreatic diversion with duodenal switch).
43846
Gastric restrictive procedure, with gastric bypass for morbid obesity; with short limb (150 cm or less) Roux-en-Y gastroenterostomy.
43847
Gastric restrictive procedure, with gastric bypass for morbid obesity; with small intestine reconstruction to limit absorption.
43848
Revision, open, of gastric restrictive procedure for morbid obesity, other than adjustable gastric restrictive device (separate procedure).
43860
Revision of gastrojejunal anastomosis (gastrojejunostomy) with reconstruction, with or without partial gastrectomy or intestine resection; without vagotomy.
43865
Revision of gastrojejunal anastomosis (gastrojejunostomy) with reconstruction, with or without partial gastrectomy or intestine resection; with vagotomy.
43881
Implantation or replacement of gastric neurostimulator electrodes, antrum, open.
43882
Revision or removal of gastric neurostimulator electrodes, antrum, open.
43886
Gastric restrictive procedure, open; revision of subcutaneous port component only.
1–10 of 16
1/2
Device approvals/mentionsmixed
TPS (Transpyloric Shuttle) FDA PMA
TPS device approved for up to 12 months weight loss therapy in specified BMI ranges
Investigational devicesmixedExperimental
EndoBarrier
Gastrointestinal liner not FDA-approved in the U.S.; investigational use only
No explicit CPT/HCPCS/ICD codes in this sectionmixed
No codes listed
Applicable CPT Codes (added)CPT
43999
Unlisted procedure, stomach
BMI categories referenced — NHLBI and clinical references
Adult BMI categories (NHLBI)Underweight: <18.5; Normal: 18.5–24.9; Overweight: 25–29.9; Obesity Class I: 30–34.9; Class II: 35–39.9; Class III: ≥40 kg/m².
Adolescent severe obesity classes (ASMBS)Class II: ≥120% of 95th percentile or BMI 35–39.9 kg/m²; Class III: ≥140% of 95th percentile or BMI ≥40 kg/m².
Use in clinical decision-makingBMI is a screening metric (weight in kg/height in m²) to define obesity categories but not a direct measure of body fatness; used with clinical judgment and comorbidity assessment.
TPS BMI eligibility
TPS (TransPyloric Shuttle) BMI eligibility
Authorization, Documentation, and Provider Requirements
Prior Authorization
Prior Authorization Required
Prior authorization is required for bariatric and metabolic procedures per InterQual® CP: Bariatric or Metabolic Surgery (and Adolescent) criteria. Providers must request prior authorization and supply documentation demonstrating that InterQual criteria are met. Use applicable CPT codes shown in the policy for reporting (see Applicable Codes); note the coding clarification that CPT 43775 should be used to report laparoscopic sleeve gastrectomy rather than unlisted CPT 43659.
Reference InterQual CP: Bariatric or Metabolic Surgery (adult and adolescent) for medical necessity determination.
Submit prior authorization requests with supporting clinical documentation and applicable procedure codes (including CPT 43775 for sleeve gastrectomy).
Prior Authorization
Revisional Surgery Authorization Requirement
Revisional bariatric procedures require prior authorization and must be preceded by a documented multidisciplinary assessment. Documentation should identify the reason for revision (anatomic versus behavioral), detail prior conservative management attempts, and present an individualized risk/benefit assessment. For GERD after prior bariatric surgery, document trials of dietary/lifestyle modification and pharmacologic acid suppression prior to considering revisional surgery.
Clinical Background and Scope
Obesity is defined clinically using body mass index (BMI) and is associated with multiple comorbidities including hypertension, type 2 diabetes, hyperlipidemia, cardiovascular disease, obstructive sleep apnea, nonalcoholic fatty liver disease, osteoarthritis, and certain cancers. Screening and referral for intensive behavioral interventions are recommended for adults with BMI ≥ 30 kg/m². Bariatric surgery aims to produce sustained weight loss to improve these obesity‑related comorbidities and may be considered in adolescents with guideline‑based BMI thresholds and multidisciplinary evaluation.
Definitions and Procedure Descriptions
Body Mass Index (BMI) definition
BMI definitionBody Mass Index (BMI) = weight in kilograms divided by height in meters squared (kg/m²).
Clinical useBMI is used as a screening tool to define obesity categories (e.g., BMI ≥40 kg/m² = Class III obesity) but should be interpreted with clinical context.
Reference sourcesClassification references include NHLBI Practical Guide and cited guideline documents in the policy references.
Multidisciplinary definition
Multidisciplinary team definitionA bariatric multidisciplinary program comprises surgeon, obesity medicine specialist, registered dietician, specialized nursing, behavioral health specialist, exercise specialist, and support services to provide comprehensive care.
Role in authorization
Policy Summary
PayerUnitedHealthcare
PolicyBariatric Surgery (for Kentucky Only)
Policy CodePolicy CS007KY.11
Change TypeCoverage language revisedcode added
Effective DateMay 1, 2025
Next Review Date
Key ActionRequest prior authorization per InterQual Bariatric/Metabolic Surgery criteria and document multidisciplinary evaluation.
Device trial limitations: Pivotal randomized trials (e.g., REDUCE for dual IGB) meet short-term efficacy endpoints but are limited by short follow-up, loss to follow-up, and device-specific adverse events that constrain conclusions about long-term safety and effectiveness.short-term RCT evidence
Additional longer-term RCTs are needed prior to routine coverage decisions.
One-anastomosis gastric bypass (OAGB/MGB) and single-anastomosis duodenal-ileal switch (SADIS/SADI) show promising weight loss in short- to mid-term reports but raise concerns about GERD, malabsorption, and nutritional complications; long-term safety and comparative RCT data remain limited.
1–5+ years typical follow-up
Long-term monitoring and nutritional follow-up are emphasized.
Stomach aspiration therapy (AspireAssist): Available systematic reviews and cohort data show ~17% total body weight loss at 1 year with maintenance to several years in some cohorts, but evidence quality is low and device-related complications necessitate caution in routine coverage.1–4 years reported
Evidence favors short- to mid-term weight loss but requires larger RCT confirmation.
Multidisciplinary evaluation requirement: All candidates for bariatric/metabolic interventions should undergo comprehensive preoperative evaluation including medical, nutritional, and psychosocial assessment with documentation of prior weight-loss attempts and a plan for long-term follow-up.N/A
ASMBS and allied societies endorse multidisciplinary assessment and center expertise.
Novel or limited-evidence procedures: Procedures judged by NICE or other regulatory/guidance bodies to have limited or inadequate evidence (e.g., EndoBarrier/DJBL, swallowable gastric balloon, SADI-S) should be used only in research settings or with special arrangements for clinical governance, consent, and audit; coverage outside these contexts is not routinely supported.research or special arrangements required
NICE interventional guidance references apply.
Device-specific FDA indications and limits: ORBERA: indicated as adjunct for adults with BMI ≥ 30 and ≤ 40 kg/m² with maximum placement of six months; TransPyloric Shuttle: PMA approval for up to 12 months for BMI 35.0–40.0 or 30.0–34.9 with comorbidity; EndoBarrier: not FDA-approved in U.S. and limited to investigational use.device-specific
Device labeling and FDA approvals inform coverage and required documentation.
NICE interventional restrictions: NICE recommends that procedures with limited evidence (e.g., EndoBarrier, SADI-S initially, swallowable gastric balloon) be used only in research settings or with special arrangements; ESG evidence is noted as safe and efficacious when combined with lifestyle changes for BMI > 30 in updated NICE guidance.research or governance required
NICE IPG statements and updates apply.
BMI 35.0–40.0 kg/m², or BMI 30.0–34.9 kg/m² with one or more obesity-related comorbid condition.
Intended use contextTPS is indicated to be used in conjunction with a diet and behavior modification program.
Regulatory statusDevice received FDA premarket approval for the above BMI ranges with up to 12 months treatment duration.
Intragastric balloon duration
Standard maximum placement durationSix months (current standard duration from insertion to removal for many FDA‑approved intragastric balloons).
Device labeling example (ORBERA)ORBERA has a maximum placement period of six months per FDA labeling.
Clinical contextIGB therapy intended as a temporary adjunct to diet, exercise, and behavioral counseling; follow-up during placement is essential to safety.
BMI examples in trials
REDUCE trial BMI range (dual IGB)Participants had BMI 30–40 kg/m² (REDUCE pivotal trial).
YOMEGA trial BMI criteria (OAGB vs RYGB)Participants had BMI ≥40 kg/m² or BMI ≥35 kg/m² with at least one comorbidity (YOMEGA study).
Trial contextsThese BMI examples reflect typical inclusion criteria used in randomized trials of IGBs and OAGB comparisons referenced in the evidence review.
Reported weight loss thresholds
Aspiration therapy (AspireAssist) typical %TWL~17% total weight loss (TWL) at 1 year in pooled studies; some cohorts maintained ~18.6% TWL out to 4 years in follow-up reports.
Orbera IGB 12‑month %EWLMeta-analysis reported ~25.44% excess weight loss (EWL) at 12 months for Orbera IGB per ASGE PIVI assessment.
IGB trial responder ratesREDUCE dual balloon trial reported significant %EWL and responder rates at 24 weeks (e.g., 25.1% ITT %EWL; 49.1% ITT responder rate ≥25% EWL).
Adolescent BMI thresholds for MBS
Primary adolescent BMI eligibility (ASMBS/AAP guidance)BMI ≥120% of the 95th percentile with a comorbidity OR BMI ≥140% of the 95th percentile for age/sex (guideline thresholds for considering MBS).
Alternative Class-based thresholdsOr use absolute Class II/III definitions (Class II: BMI ≥35 or 120% of 95th percentile with significant disease; Class III: BMI ≥40 or 140% of 95th percentile).
Eligibility considerationsMultidisciplinary evaluation, center expertise, and individualized assessment (including psychosocial and growth considerations) are required for adolescents.
Adult NICE BMI criteria
NICE adult surgical BMI thresholdsOffer bariatric surgery for BMI ≥40 kg/m² OR BMI 35–39.9 kg/m² with a significant health condition that could improve if weight is lost.
Expedited consideration and lower thresholdsConsider expedited assessment for BMI ≥35 or BMI 30.0–34.9 kg/m² with recent‑onset (≤10 years) type 2 diabetes; consider lowering BMI thresholds by 2.5 kg/m² for certain ethnic groups at higher cardiometabolic risk.
Pediatric noteSurgery generally not recommended in children except in exceptional, physiologically mature cases per NICE guidance.
BMI examples cited
Common BMI examples cited for surgical considerationExamples cited include BMI ≥40 kg/m², or BMI 35–39.9 kg/m² with significant comorbidity (NICE guidance).
Device-specific BMI examplesORBERA indicated for adults with BMI ≥30 and ≤40 kg/m²; TransPyloric Shuttle indicated for BMI 35.0–40.0 or 30.0–34.9 with comorbidity.
Expedited consideration noteNICE suggests expedited consideration for BMI 35+ or 30.0–34.9 with recent-onset T2DM (≤10 years).
Provide evidence of multidisciplinary evaluation (surgical, medical, nutritional, and behavioral health inputs) and MBSAQIP center referral when applicable.
Document prior conservative therapy including diet, exercise, behavior modification, and acid-reducing medications for GERD.
Detail specific anatomic findings (imaging, endoscopy) that justify revision versus behavioral contributors to inadequate weight loss or weight regain.
Prior Authorization
Prior Authorization for Procedures With Limited Long‑Term Evidence
Procedures and devices that lack robust long‑term randomized controlled trial evidence or have limited safety data—such as various novel endoscopic, device, or bypass techniques—require prior authorization and heightened documentation. Authorization may be denied if evidence of safety and sustained efficacy is insufficient.
When evidence is limited, provide long-term outcome data, SAE rates, device-specific approval/labeling, and rationale for use in the individual patient.
Documentation Required
Approval / Evidence Documentation
Approval decisions require documentation that the device or procedure has evidence supporting safety and effectiveness (FDA approval when applicable, and meeting professional society efficacy/safety thresholds). For FDA‑cleared devices, include specific labeling indications and placement/time limits in the submission.
If device is FDA‑approved (e.g., ORBERA IGB, TransPyloric Shuttle, OverStitch), include PMA/510(k) references and the labeled indications (e.g., ORBERA: adults BMI ≥30–≤40 kg/m2, adjunct to supervised diet/behavior modification, maximum placement 6 months).
If relying on society guidance (ASGE/ASMBS), include how the device meets PIVI or other threshold statements and planned long‑term follow-up mechanisms.
Documentation Required
Device Indication and Prior Conservative Therapy Documentation
For procedures involving FDA‑marketed devices (e.g., ORBERA, LAP‑BAND, TransPyloric Shuttle, OverStitch), prior conservative therapy must be documented consistent with device labeling and society guidance. Documentation should show failed attempts at supervised diet, exercise, behavior modification, and any indicated medical therapy prior to device implantation.
Include prior weight‑loss program details (duration, intensity, outcomes) and pharmacotherapy trials when applicable.
For adjustable gastric bands, document that patient is ≥18 years and meets FDA labeling criteria when relevant.
Denial Risk
Procedures Listed as Unproven / Not Medically Necessary
Certain procedures are identified in this policy as unproven or not medically necessary for obesity due to insufficient evidence of efficacy or safety. These procedures may not be covered and are at high risk for denial if requested without compelling, high‑quality supporting evidence.
Requests for these procedures should include rationale, detailed informed‑consent discussion of investigational status, and any available trial data.
Denial Risk
Failure to Perform a Thorough Multidisciplinary Assessment May Trigger Denial
Failure to perform and document a thorough multidisciplinary assessment prior to revisional procedures or novel interventions may result in denial. Documentation must show engagement of appropriate team members (surgeon, medical weight‑management specialist, nutritionist, behavioral health) and clear justification for the chosen intervention.
Include preoperative psychosocial evaluation, behavioral health input, and plan for postoperative long‑term follow‑up.
When treating adolescents, document referral to comprehensive pediatric/metabolic bariatric center and family‑centered evaluation per guidelines.
Denial Risk
Insufficient Evidence May Trigger Denial
Procedures lacking sufficient high‑quality evidence or with concerning safety profiles may be denied. Evidence limitations include small single‑center RCTs, short follow‑up, inconsistent outcome reporting, or high rates of revision and adverse events.
Examples of denial triggers: high revision rates after LGCP, major adverse events with gastrointestinal liners (hepatic abscess, GI hemorrhage, pancreatitis), devices with unmet RCT endpoints (e.g., VBLOC).
Provide robust comparative data, long‑term follow‑up, and safety surveillance to support coverage of procedures with uncertain evidence.
Denial Risk
Gastric Electrical Stimulation Considered Investigational Pending Further Evidence
Gastric electrical stimulation (GES) is considered investigational pending larger randomized trials with long‑term follow‑up. Current studies are small, early‑phase, or nonrandomized and do not conclusively demonstrate superiority to conservative therapies or established surgical procedures.
If GES is requested, include full trial data, SAE profile, device approval status, planned follow‑up, and specific patient selection rationale.
Describe alternatives attempted and why GES is preferred in the individual case.
Denial Risk
LGCP Revision / Long‑Term Failure Risk
Some procedures demonstrate high rates of long‑term weight regain and revision (for example LGCP), which increases the risk of coverage denial for use as a primary preferred procedure. Provide data on expected revision rates and plans for long‑term monitoring if requesting coverage.
Document prior discussions with the patient about likelihood of weight regain and need for further surgery.
Include institutional experience, volume, and outcome data if requesting coverage for LGCP.
Denial Risk
Insufficient Long‑Term Evidence
Procedures such as OAGB/MGB and SADI/SADS currently have limited long‑term evidence; authorization requests should include long‑term outcome data, nutritional monitoring plans, and strategies to mitigate malabsorptive complications.
Provide five‑year outcomes if available, nutritional surveillance protocols, and center expertise in managing malabsorptive sequelae.
Highlight patient selection rationale and alternatives considered.
Denial Risk
Safety‑Related Denial Risk
When safety concerns are prominent (e.g., device obstructions, GI hemorrhage, liver abscess, pancreatitis, high SAE or explantation rates), authorization may be denied unless comprehensive risk mitigation and follow‑up plans are provided.
For gastrointestinal liners and similar devices, include plans for monitoring for hepatic abscess and bowel obstruction and prompt removal protocols.
Report institutional SAE rates and patient counseling documentation regarding risks and signs/symptoms requiring urgent evaluation.
Denial Risk
Contraindications and Eligibility Risks
Relative contraindications and eligibility risks should be documented and considered in authorization decisions. Absolute and relative contraindications per society guidance and device labeling must be addressed in the clinical record.
Examples of relative contraindications: severe heart failure, unstable coronary disease, end‑stage lung disease, active cancer, cirrhosis with portal hypertension, uncontrolled substance use, severely impaired intellectual capacity.
For adjustable gastric bands, document age restrictions and FDA contraindications.
Prior Authorization
Procedures Limited to Research or Special Arrangements
Procedures judged by external guidance (e.g., NICE) to have limited evidence should be performed only with special arrangements for governance, consent, audit, or within research protocols. Authorization for such procedures is typically limited to research or special arrangements.
Examples: duodenal‑jejunal bypass liner (EndoBarrier®) and single‑anastomosis duodeno‑ileal bypass with sleeve gastrectomy (SADI‑S) per NICE recommendations.
When requesting coverage under special arrangements, submit IRB/clinical governance approvals, research protocol, and consent forms.
Note
Regulatory and Contractual Precedence
Coverage decisions must conform to federal, state, or contractual benefit plan requirements. In the event of a conflict between this policy and applicable federal/state/contractual terms, the federal/state/contractual requirements govern.
Verify plan‑specific benefit language and any applicable mandates before authorization.
UnitedHealthcare may apply InterQual criteria, and when InterQual lacks applicable criteria, may use UnitedHealthcare Medical Policies, Coverage Determination Guidelines, or Utilization Review Guidelines approved by the Kentucky Department for Medicaid Services.
Documentation Required
Preoperative Evaluation and Procedure‑Specific Documentation
Documentation submitted for authorization should include comprehensive preoperative evaluation and procedure‑specific details. Clinical records should support patient selection and risk assessment consistent with guidelines and study criteria.
Preoperative evaluation: obesity‑focused history, weight history, prior weight‑loss attempts, physical exam, pertinent labs and diagnostics, and psychosocial assessment.
Include planned postoperative follow‑up, nutritional monitoring, and long‑term weight‑management plans.
Documentation Required
Clinical Outcomes, Follow‑Up, and Informed Consent Documentation
Clinical outcomes, follow‑up, and informed consent documents should be included in the authorization package. Provide prior outcome data if requesting coverage for less‑established procedures and document that patients were counseled on expected benefits, alternatives, and potential serious adverse events.
Provide prior institutional outcome metrics (weight/BMI change, comorbidity resolution, SAE rates, revision rates) and duration of follow‑up.
Include signed informed consent detailing procedure risks, potential for explantation or reoperation, and expected need for long‑term surveillance.
Documentation Required
Document Device Approvals and Indications
Device approvals, labeled indications, and time‑limited use conditions must be documented (e.g., FDA PMA/510(k) references and maximum placement periods). When device use is requested outside labeled indications, include justification and supporting evidence.
Examples: ORBERA PMA indication and maximum 6‑month placement; TransPyloric Shuttle PMA indications.
For off‑label device use, provide peer‑reviewed evidence, institutional review, and patient consent acknowledging off‑label use.
Note
Use of InterQual and Alternate Criteria
UnitedHealthcare uses InterQual® for primary medical/surgical criteria and ASAM for substance use in benefits administration. If InterQual does not have applicable criteria, UnitedHealthcare may use its own Medical Policies, Coverage Determination Guidelines, or Utilization Review Guidelines as approved by the Kentucky Department for Medicaid Services.
Include the InterQual criteria reference and specific criteria met when submitting prior authorization.
If relying on alternate UnitedHealthcare guidelines, reference the policy/version used in the review.
Step Therapy
Non‑Surgical First‑Line Therapy
First‑line (non‑surgical) treatments — dietary therapy, physical activity, behavior modification, and medication management — should be documented as tried and unsuccessful before considering surgical or device interventions, unless guidelines or clinical circumstances (including adolescent criteria) specify otherwise.
For adults and adolescents, document prior participation in supervised weight‑loss programs, duration, and outcomes.
For adolescents, prior attempts at medical programs should not be an absolute barrier; document multidisciplinary evaluation and individualized decision‑making.
Step Therapy
Non‑Surgical Management and Stepwise Therapy Before Device Use
For device therapies (e.g., IGB), document prior non‑surgical management attempts and use stepwise care. Many devices are indicated as adjuncts to lifestyle modification; authorization packages should include plans for concurrent behavioral, nutritional, and pharmacologic supports.
IGB candidacy should include failed conventional strategies, commitment to supervised diet/exercise programs, and plans for PPI prophylaxis and antiemetic management as per society guidance.
When a device is used as a bridge to surgery, document intended timing of device removal and definitive surgical plan if applicable.
Multidisciplinary evaluation and documentation are required prior to bariatric and many device‑based interventions, particularly for adolescents and revisional surgery.
Center expertiseReferral to centers experienced in metabolic and bariatric surgery with pediatric capability is recommended for adolescent MBS candidates.
OSA severity definitions
OSA severity definitionsMild: AHI/RDI ≥5 and <15; Moderate: AHI/RDI ≥15 and ≤30; Severe: AHI/RDI >30 events/hour.
Use in eligibilityOSA severity is a listed comorbidity that may factor into surgical candidacy decisions for adolescents and adults.
Revisional bariatric surgery definitions
Revisional surgery definitionsConversion: change from one bariatric procedure to another; Corrective: modify prior procedure to achieve intended outcome or correct complication; Reversal: restore original anatomy.
Authorization considerationsRevisional procedures require multidisciplinary assessment to document anatomic versus behavioral causes of failure and individualized risk/benefit analysis.
BPD/DS definition
BPD/DS descriptionBiliopancreatic diversion with duodenal switch is primarily malabsorptive with removal of the greater curvature and creation of intestinal limbs with a short common channel (50–100 cm) to limit absorption.
Clinical implicationsProcedure produces greater weight loss for very high BMI but is associated with long-term nutritional deficiencies requiring follow-up.
LMGBP/OAGB definition
OAGB/LMGBP descriptionOne‑anastomosis (mini) gastric bypass creates a gastric tube with a single gastroenteric anastomosis; unlike RYGB, bile is not diverted and may cause bile reflux, diarrhea, steatorrhea, and nutritional disorders.
Evidence concernsShort- to medium-term data exist but long-term safety and nutritional outcomes beyond 5 years are insufficient; randomized data (YOMEGA) used BMI ≥40 or ≥35 with comorbidity for inclusion.
ESG definition
ESG definitionEndoscopic Sleeve Gastroplasty uses endoscopic suturing (e.g., OverStitch) to reduce gastric volume via the mouth without resection, producing a tube‑shaped stomach.
Evidence statusEvidence is limited to observational studies and systematic reviews showing short- to mid-term weight loss; RCTs and long-term outcomes are lacking.
Comparative effectiveness note
Comparative effectiveness noteRCTs and systematic reviews compare RYGB, SG, AGB, and other procedures showing differing weight loss and complication profiles; long‑term comparative evidence remains limited.
Implication for coverageProcedure choice should consider comparative outcomes, comorbidity impact, and long‑term follow‑up needs.
Investigational interventions list
Investigational interventions listProcedures considered investigational include bariatric artery embolization, many gastric electrical stimulation systems, gastrointestinal liners (EndoBarrier/DJBL), vagus nerve blocking, transoral devices (TPS), ESG, AspireAssist, and others pending robust RCTs and long‑term safety data.
Coverage implicationThese interventions are described as investigational or not medically necessary until stronger evidence demonstrates sustained safety and efficacy.
Dual intragastric balloon definition
Dual intragastric balloon (DBS/DUO)An endoscopically placed dual intragastric balloon system evaluated in the REDUCE trial showing greater short‑term weight loss versus diet/exercise alone (e.g., %EWL and responder rates at 24 weeks).
Clinical contextDevice is temporary and used as an adjunct to lifestyle intervention; additional RCTs with longer follow‑up are needed.
OAGB definition and concerns
OAGB definition and concernsOne‑anastomosis gastric bypass (OAGB/MGB) involves a single gastroenteric anastomosis and may increase risk of GERD, diarrhea, steatorrhea, and nutritional disorders; long‑term safety requires further study.
Trial BMI examplesYOMEGA enrolled patients with BMI ≥40 or ≥35 with comorbidity, informing typical trial inclusion criteria.
SADIS/SADI definition and concerns
SADIS/SADI definition and concernsSingle‑anastomosis duodenal‑ileal switch variants are hypoabsorptive procedures with promising weight loss but notable malabsorption/nutritional complications and limited long‑term RCT evidence.
Long‑term monitoring needPatients require prolonged nutritional follow‑up due to risk of malabsorption and deficiencies.
AspireAssist definition
AspireAssist (stomach aspiration) definitionAspireAssist is a percutaneous gastric aspiration system allowing post‑meal aspiration of stomach contents to induce weight loss; studies report ~17% TWL at 1 year and maintenance to ~18.6% at up to 4 years in selected cohorts.
Safety profileReported pooled SAE rate ~4.1% including device‑related complications and persistent fistula in some cases; evidence limited by small, observational studies.
TPS device description
TPS device descriptionTranspyloric Shuttle is a non‑balloon, space‑occupying silicone device tethered in the stomach, delivered and removed endoscopically, with an intended 12‑month treatment duration.
Evidence statusFDA PMA granted for specified BMI ranges, but independent longer‑term RCT confirmation recommended due to limited evidence.
ESG description
ESG description (OverStitch)Endoscopic Sleeve Gastroplasty uses the OverStitch endoscopic suturing system to reduce gastric volume via endoscopic sutures without resection, producing weight loss in observational studies.
Regulatory noteOverStitch received 510(k) clearance for endoscopic suturing (see FDA summary) and is used in ESG procedures.
Vagus nerve blocking description
Vagus nerve blocking (vBloc/Maestro)Implantable neuroregulator delivering intermittent vagal nerve blockade intended to reduce appetite and weight; pivotal trials show mixed efficacy and need longer‑term data.
Trial outcomesReCharge trial results: weight loss benefit vs sham at 12 months but did not meet prespecified coprimary efficacy objectives; longer‑term durability unclear.
DJBL / EndoBarrier description
DJBL / EndoBarrier descriptionDuodenal‑jejunal bypass liner is an endoscopically placed impermeable sleeve that bypasses proximal small intestine to affect nutrient absorption and glycemic control; associated with serious AEs (e.g., liver abscess, GI hemorrhage) and frequent weight regain after removal in some series.
Regulatory statusEndoBarrier has had safety concerns and trials with variable outcomes; not FDA‑approved for routine use in the U.S. per policy discussion.
IGB definition
IGB definitionIntragastric balloon is a temporary, endoscopically placed space‑occupying device intended as an adjunct to lifestyle modification; FDA‑approved devices (e.g., ORBERA) have maximum placement of six months and RCT evidence demonstrates short‑term weight loss benefit.
Evidence summaryLevel 1 RCT data support IGB utility for short‑term weight loss; ASGE PIVI criteria met for Orbera in pooled analyses (e.g., ~25% EWL at 12 months).
ORBERA device definition and summary
ORBERA device summaryORBERA intragastric balloon indicated as adjunct to weight reduction in adults with BMI ≥30 and ≤40 kg/m²; maximum placement six months per FDA labeling.
Coding and accreditation contextPolicy references CPT codes for endoscopic IGB placement/removal (e.g., 43290, 43291, 0813T) and notes applicable coding clarifications (policy added CPT 43999 to codes list).
MBSAQIP
MBSAQIP referenceMetabolic and Bariatric Surgery Accreditation and Quality Improvement Program (MBSAQIP) is referenced as the accreditation framework for centers and quality reporting.
Role in care deliveryReferral to MBSAQIP‑accredited centers is advised for comprehensive multidisciplinary care and long‑term follow‑up of bariatric patients.